Загрузка...

The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies

Teriflunomide is a once-daily oral immunomodulator approved for relapsing-remitting multiple sclerosis (MS). The objective of this post hoc analysis of the phase 3, pooled TEMSO (NCT00134563) and TOWER (NCT00751881) dataset is to evaluate the effect of teriflunomide treatment on annualised relapse r...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Mult Scler
Главные авторы: Freedman, Mark S, Wolinsky, Jerry S, Comi, Giancarlo, Kappos, Ludwig, Olsson, Tomas P, Miller, Aaron E, Thangavelu, Karthinathan, Benamor, Myriam, Truffinet, Philippe, O’Connor, Paul W
Формат: Artigo
Язык:Inglês
Опубликовано: SAGE Publications 2017
Предметы:
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5891690/
https://ncbi.nlm.nih.gov/pubmed/28304217
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1352458517695468
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!